Tradestie Institutional Equity Comparison Engine

BMRA vs PACB โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

BMRA Overall Edge

BMRA Captures Institutional Edge (2โ€“1 Pillars ยท 4โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Biomerica Inc (BMRA) driven by superior Growth & Margin, Options & Structure while PACB counters with relative strength in Momentum & Technical. Fundamentally, BMRA trades at N/M Forward P/E with -125.2% operating margin (-8.3% YoY revenue) versus PACB at N/M Forward P/E and -333.0% operating margin (+5.5% YoY). In options structure, BMRA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against PACB sits in BREAKDOWN (47th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
BMRA N/M vs PACB N/M Fwd P/E
Growth & Margin Winner BMRA
Op Margin -125.2% vs -333.0% ยท YoY -8.3% vs +5.5%
Momentum & Technical Winner PACB
1Y -45.6% vs +15.6% ยท 52W Pos 5% vs 34%
Options & Structure Winner BMRA
UNCLASSIFIED (N/A IV) vs BREAKDOWN (47th %ile IV)
BMRA NASDAQ
Biomerica Inc
In Vitro & In Vivo Diagnostic Substances
$1.36
+0.0% 1D
Market Cap $6.0M
1M Return -26.49%
1Y Return -45.6%
Forward P/E N/M
Unified AI Score
44.5 / 100 HOLD
Tech 40.0 Fund 47.0 Flow 50.0 Mom 44.0
PACB NASDAQ
Pacific Biosciences of California, Inc.
Laboratory Analytical Instruments
$1.89
-3.83% 1D
Market Cap $615.1M
1M Return +8.96%
1Y Return +15.64%
Forward P/E N/M
Unified AI Score
42.0 / 100 HOLD
Tech 15.0 Fund 36.0 Flow 57.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: BMRA -45.6% PACB +15.64% Spread: +61.24 pp (PACB Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period BMRA Revenue PACB Revenue BMRA Op. Margin PACB Op. Margin Margin Edge
FY2019 $10M $90M -46.4% -110.6% BMRA
FY2020 $10M $80M -41.0% -132.3% BMRA
FY2021 $10M $130M -104.2% -161.2% BMRA
FY2022 $20M $130M -24.0% -239.4% BMRA
FY2023 $10M $200M -135.3% -166.8% BMRA
FY2024 $10M $150M -117.6% -308.0% BMRA
FY2025 $10M $160M -96.7% -346.2% BMRA
FY2026 $0M N/A -119.5% N/A BMRA

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: BMRA (4) vs PACB (4)
Institutional Metric BMRA PACB Criterion Row Winner
Market Capitalization Scale $6.0M $615.1M Larger Scale PACB
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -8.3% +5.5% Higher Growth PACB
Operating Margin (TTM) Profitability -125.2% -333.0% Higher Margin BMRA
Net Profit Margin Profitability -115.5% -81.3% Higher Margin PACB
Return on Equity (ROE) Capital Efficiency -113.8% -929.3% Higher ROE BMRA
52-Week Range Position Momentum 5% ($1โ€“$3) 34% ($1โ€“$3) Stronger Trend PACB
Beta / 30D Volatility Risk Regime 0.67ฮฒ ยท 62% Vol 2.27ฮฒ ยท 112% Vol Lower Realized Risk BMRA
Unified Institutional Score Composite Signal 44.5 / 100 (HOLD) 42.0 / 100 (HOLD) Higher Composite BMRA

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full BMRA vs PACB Buy Guide
BMRA UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live BMRA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
PACB BREAKDOWN
12d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 47th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live PACB Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither BMRA nor PACB registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.